Androgen Receptor Signaling Inhibitors

Fillmore and his collaborators have evaluated the comparative efficacy of androgen receptor signaling inhibitors in patients with metastatic castration-resistant prostate cancer. His research indicates that enzalutamide is associated with improved overall survival and more rapid prostate-specific antigen response than abiraterone acetate. These findings are particularly significant for frail patients or those with extensive comorbidities, suggesting a preferential role for enzalutamide in these clinical populations.